UroGen Pharma
URGN
31 hedge funds and large institutions have $145M invested in UroGen Pharma in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 4 closing their positions.
250% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 4
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
70% more capital invested
Capital invested by funds: $85.2M → $145M (+$59.5M)
48% more funds holding
Funds holding: 21 → 31 (+10)
4.27% less ownership
Funds ownership: 39.41% → 35.14% (-4.3%)
17% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MMH
Menora Mivtachim Holdings
Ramat Gan,
Israel
|
+$9.72M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$2.21M |
| 3 |
DP
DSAM Partners
London,
United Kingdom
|
+$1.64M |
| 4 |
BII
Bainco International Investors
Boston,
Massachusetts
|
+$1.6M |
| 5 |
LSC
Lyon Street Capital
Sausalito,
California
|
+$921K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$10.2M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$6.36M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$903K |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$726K |
| 5 |
Norges Bank
Oslo,
Norway
|
-$631K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
State of Tennessee, Department of Treasury
Nashville,
Tennessee
| $158K | +$111K | +5,010 | New |
|
27
Royal Bank of Canada
Toronto,
Ontario, Canada
| $55K | +$38.6K | +1,750 | New |
|
|
28
Norges Bank
Oslo,
Norway
| $42K | -$631K | -28,566 | -96% |
|
|
PA
29
Parallel Advisors
San Francisco,
California
| $35K | +$17.7K | +800 | New |
|
30
UBS Group
Zurich,
Switzerland
| $32K | +$13.8K | +627 | +168% |
|
|
CCA
31
Catalyst Capital Advisors
Huntington,
New York
| $12K | – | – | – |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $10K | +$861 | +39 | +14% |
|
|
HIM
33
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
| – | -$6.36M | -352,300 | Closed |
|
|
34
Alyeska Investment Group
Chicago,
Illinois
| – | -$903K | -50,000 | Closed |
|
|
PL
35
Parkwood LLC
Cleveland,
Ohio
| – | -$500K | -27,694 | Closed |
|
URGN Hedge Fund Activity: Q3 2017 in Review
31 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2017, worth a combined $145M — up 70% from $85.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new URGN positions and 4 closed out — a net gain of 10 holders — while 5 added to existing stakes and 6 trimmed.
The largest buyer was Menora Mivtachim Holdings, adding an estimated $9.72M. The largest seller was Wellington Management Group, cutting an estimated $10.2M.
- 31 institutional investors held UroGen Pharma (URGN) as of Q3 2017, up from 21 in Q2 2017.
- Funds reported $145M of UroGen Pharma stock for Q3 2017, up 70% quarter-over-quarter.
- 14 funds opened new UroGen Pharma positions in Q3 2017 and 4 closed out, a net change of +10 holders.
- The largest UroGen Pharma buyer in Q3 2017 was Menora Mivtachim Holdings, an estimated $9.72M added.
- The largest UroGen Pharma seller in Q3 2017 was Wellington Management Group, an estimated $10.2M sold.
Based on aggregated 13F filings for Q3 2017.